Skip to main content
SpringerLink
Log in

Task Force Report on Obstetric Antiphospholipid Syndrome

  • Chapter
  • First Online:
Antiphospholipid Syndrome

  • 639 Accesses

Abstract

The obstetric criteria for antiphospholipid syndrome (APS) were first formalized in 1999 at the 10th International Congress on Antiphospholipid Antibodies (aPL). In 2010, the Organizing Committee for the upcoming 13th International Congress on aPL formed an Obstetric APS Task Force. The intent was to kindle discussion regarding obstetric APS prior to the meeting and then to engender participation among interested experts and attendees at a half-day Task Force meeting to be held the day before the official start of the Congress. The Task Force concluded that there is virtually no evidence from properly designed trials to guide clinicians with regard to prevention of fetal death, severe preeclampsia, or placental insufficiency attributed to APS. Also, no clear consensus was reached with regard to resolving discrepancies in existing trials of heparin treatment for recurrent early miscarriage attributed to APS. A majority of Task Force members were in agreement that studies in the field of APS must be carefully planned with regard to such critical elements as case and control matching and inclusion and exclusion criteria. Moreover, the ability to perform repeat testing and confirmatory testing in a central laboratory would be mandatory.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.

    Article  PubMed  CAS  Google Scholar 

  2. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010;376:1498–509.

    Article  PubMed  CAS  Google Scholar 

  3. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol. 1996;174:1584–9.

    Article  PubMed  CAS  Google Scholar 

  4. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br Med J. 1997;314:253–7.

    Article  CAS  Google Scholar 

  5. Clifford K, Rai R, Watson H, Regan L. Pregnancy: an informative protocol for the investigation of recurrent miscarriage: preliminary experience of 500 consecutive cases. Hum Reprod. 1994;9:1328–32.

    PubMed  CAS  Google Scholar 

  6. Branch DW, Silver RM, Porter TF. Obstetric antiphospholipid syndrome: current uncertainties should guide our way. Lupus. 2010;19:446–52.

    Article  PubMed  CAS  Google Scholar 

  7. Bruce IN, Clark-Soloninka CA, Spitzer KA, Gladman DD, Urowitz MB, Laskin CA. Prevalence of antibodies to beta2-glycoprotein I in systemic lupus and their association with antiphospholipid antibody syndrome criteria: a single center study and literature review. J Rheumatol. 2000;27:2833–7.

    PubMed  CAS  Google Scholar 

  8. Chauleur C, Galanaud JP, Alonso S, et al. Ovservational study of pregnant women with a previous spontaneous abortion before the 10th gestation week with and without antiphospholipid antibodies. J Throm Haemost. 2010;8:699–706.

    Article  CAS  Google Scholar 

  9. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol. 2002;100:408–13.

    Article  PubMed  CAS  Google Scholar 

  10. Laskin CA, Spitzer K, Clark C, et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA trial. J Rheumatol. 2009;36:279–87.

    Article  PubMed  CAS  Google Scholar 

  11. Kaandorp SP, Goddijn M, van der Post JAM, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Eng J Med. 2010;362:1586–96.

    Article  CAS  Google Scholar 

  12. Clark P, Walker ID, Langhorne P, et al. SPIN: the Scottish pregnancy intervention study: a multicentre randomized trial of low molecular weight heparin and low dose aspirin in women with recurrent miscarriage. Blood. 2010;115:4162–7.

    Article  PubMed  CAS  Google Scholar 

  13. Branch DW, Silver RM, Blackwell JL, Reading JC, Scott JR. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol. 1992;80:614–20.

    PubMed  CAS  Google Scholar 

  14. Clark EA, Silver RM, Branch DW. Do antiphospholipid antibodies cause preeclampsia and HELLP syndrome? Curr Rheumatol Rep. 2007;9:219–25.

    Article  PubMed  CAS  Google Scholar 

  15. Dreyfus M, Hedelin G, Kutnahorsky R, et al. Antiphospholipid antibodies and preeclampsia: a case-control study. Obstet Gynecol. 2001;97:29–34.

    Article  PubMed  CAS  Google Scholar 

  16. Branch DW, Porter TF, Rittenhouse L, et al. Antiphospholipid antibodies in women at risk for preeclampsia. Am J Obstet. 2001;184:825–32.

    Article  CAS  Google Scholar 

  17. Pattison NS, Chamley LW, McKay EJ, et al. Antiphospholipid antibodies in pregnancy: prevalence and clinical associations. Br J Obstet Gynaecol. 1993;100:909–13.

    Article  PubMed  CAS  Google Scholar 

  18. Yasuda M, Takakuwa K, Tokunaga A, Tanaka K. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy. Obstet Gynecol. 1995;86:555–9.

    Article  PubMed  CAS  Google Scholar 

  19. Lynch A, Marlar R, Murphy J, et al. Antiphospholipid antibodies in predicting adverse pregnancy outcome. A prospective study. Ann Inten Med. 1994;120:470–5.

    Article  CAS  Google Scholar 

  20. Katano K, Aoki A, Sasa H, et al. Beta 2-Glycoprotein I-dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women. Hum Reprod. 1996;11:509–12.

    Article  PubMed  CAS  Google Scholar 

  21. Faden D, Tincani A, Tanzi P, et al. Anti-beta 2 glycoprotein I antibodies in a general obstetric population: preliminary results on the prevalence and correlation with pregnancy outcome. Eur J Obstet Gynecol Reprod Biol. 1997;73:37–42.

    Article  PubMed  CAS  Google Scholar 

  22. Yamada H, Atsumi T, Amengual O, et al. Glycoprotein-I antibody increases the risk of pregnancy-induced hypertension: a case-controlled study. J Reprod Immunol. 2010;84:95–9. epub ahead of print.

    Article  PubMed  CAS  Google Scholar 

  23. Nodler J, Moolamalla SR, Ledger SM, et al. Elevated antiphospholipid antibody titers and adverse pregnancy outcomes: analysis of a population-based hospital dataset. BMC Pregnancy Childbirth. 2009;9:11–8.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  24. Bates SM, Greer IA, Pabinger I, et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:844–66.

    Article  CAS  Google Scholar 

  25. Chan AT, Manson JE, Feskanich D, Stampfer MJ, Colditz GA, Fuchs CS. Long term aspirin use and mortality in women. Arch Int Med. 2007;167:562–72.

    Article  Google Scholar 

  26. Erkan D, Harrison MJ, Levy R, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 2007;56:2382–91.

    Article  PubMed  CAS  Google Scholar 

  27. Rey E, Garneau P, David M, et al. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost. 2009;7:58–64.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

In addition to the authors, the Task Force Members for Obstetric APS were the following: Alijotas-Reig, Jaume, MD, PhD (Vall d’Hebron University Hospital, Universitat Autònoma, Barcelona, Spain), Alba, Paula, MD, PhD (Universidad Nacional de Cordoba, Cordoba, Argentina), Buyon, Jill, MD (Hospital for Joint Diseases, New York, NY), Cohen, Hannah, MD (University College London Hospitals, London, UK), Contreras, Juan A. MD, de Jesus, Guilherme MD (Universidade do Estado do Rio de Janeiro, Brazil), de Jesus, Nilson Ramires MD (Universidade do Estado do Rio de Janeiro, Brazil), Farran-Codina, Inma, MD, PhD, Grand, Beatriz, MD (University of Buenos Aires, Buenos Aires, Argentina), Greco, Thomas P., MD (Saint Mary’s Hospital, Waterbury, CT), Harraca, Monica G., MD, Kutteh, Billy, MD, PhD (University of Tennessee, Memphis, TN), Levy, Roger A., MD, PhD (Universidade do Estado do Rio de Janeiro, Brazil), Lockshin, Michael, MD (Hospital for Special Surgery, New York, NY), Makatsariya, Alexander, MD, PhD, Maria-Otero, Ana, MD, Michelon, Tatiana, MD, PhD, Pappalardo, Cecilia, MD (Halitus Medical Institute, Buenos Aires, Argentina), Parke, Ann, MD (University of Connecticut Health Center, Farmington, CT), Pierangeli, Silvia,PhD (University of Texas Medical Branch, Galveston, TX), Ruiz, Itziar Garcia, MD, Salmon, Jane, MD (Hospital for Special Surgery, New York, NY), Sarto, Adriana, MD (Halitus Medical Institute, Buenos Aires, Argentina), Silver, Robert, MD (University of Utah Health Sciences Center, Salt Lake City, UT), Zarzoso, Cristina, MD (Vall d’Hebron University Hospital, Universitat Autònoma, Barcelona, Spain).

Author information

Authors and Affiliations

  1. Department of Obstetrics & Gynecology, University of Utah Hospital, 30 North 1900 East 2B200 SOM, Salt Lake City, UT, 84132, USA

    D. Ware Branch MD

  2. Department of Clinical Research, ReproSource, Inc., Woburn, MA, USA

    Benjamin Leader MD, PhD

  3. Department of Medicine, Obstetrics & Gynecology and Immunology, University of Toronto, Toronto, ON, Canada

    Carl A. Laskin MD

Authors
  1. D. Ware Branch MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Benjamin Leader MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carl A. Laskin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Ware Branch MD .

Editor information

Editors and Affiliations

  1. The Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, New York, NY, USA

    Doruk Erkan

  2. University of Texas Medical Branch, 301 University Boulevard, Galveston, 77555-0883, Texas, USA

    Silvia S. Pierangeli

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Branch, D.W., Leader, B., Laskin, C.A. (2012). Task Force Report on Obstetric Antiphospholipid Syndrome. In: Erkan, D., Pierangeli, S. (eds) Antiphospholipid Syndrome. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-3194-7_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-3194-7_9

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4614-3193-0

  • Online ISBN: 978-1-4614-3194-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation